Topisches Mitomycin C zur Rezidivprophylaxe von Haze nach erneuter Excimer-Laser-photorefraktiver Keratektomie (PRK) - Klinische Pilotstudie an 5 Patienten1
Abstract:Topical applied mitomycin C seems to be a promising therapy to prevent recurrent haze after a second PRK procedure. As mitomycin C can be associated with a variety of serious complications, it should only be used in patients with high risk of haze.
“…The 9-month follow-up revealed that the surgically treated corneas remained clear. 18 Majmudar et al 31 demonstrated that topical application of mitomycin C (0.02%) successfully prevented the recurrence of epithelial fibrosis after debridement. Eight corneas undergoing mitomycin C treatment after debridement remained clear, with no recurrence or adverse reaction throughout the follow-up periods (6 -25 months).…”
Section: Discussionmentioning
confidence: 99%
“…16 Mitomycin C reduces keratocytes in the anterior stroma after corneal refractive surgery, leading to a decrease in activated fibroblasts, production of extracellular matrix, and formation corneal haze. [17][18][19][20] Mitomycin C, an alkylating antibiotic agent derived from Streptomyces caespitosus, blocks DNA and RNA replication and protein synthesis. The compound is metabolized by liver enzymes to form an alkylating agent that nonspecifically crosslinks with DNA in a cell-cycle-dependent manner.…”
Mitomycin C induced apoptosis, not necrosis, in cultured corneal keratocytes through the caspase pathway-specifically, caspase-8 and -9-related to the mitochondrial pathway.
“…The 9-month follow-up revealed that the surgically treated corneas remained clear. 18 Majmudar et al 31 demonstrated that topical application of mitomycin C (0.02%) successfully prevented the recurrence of epithelial fibrosis after debridement. Eight corneas undergoing mitomycin C treatment after debridement remained clear, with no recurrence or adverse reaction throughout the follow-up periods (6 -25 months).…”
Section: Discussionmentioning
confidence: 99%
“…16 Mitomycin C reduces keratocytes in the anterior stroma after corneal refractive surgery, leading to a decrease in activated fibroblasts, production of extracellular matrix, and formation corneal haze. [17][18][19][20] Mitomycin C, an alkylating antibiotic agent derived from Streptomyces caespitosus, blocks DNA and RNA replication and protein synthesis. The compound is metabolized by liver enzymes to form an alkylating agent that nonspecifically crosslinks with DNA in a cell-cycle-dependent manner.…”
Mitomycin C induced apoptosis, not necrosis, in cultured corneal keratocytes through the caspase pathway-specifically, caspase-8 and -9-related to the mitochondrial pathway.
“…Mitomycin C and steroids have been found to prevent corneal opacity, and the former has been effective in several clinical trials. [29][30][31][32] In this study, we tested ceramides to determine their effect on rabbit corneal fibroblasts.…”
Section: Cornea • Volume 24 Number 1 January 2005mentioning
“…[15][16][17][18][19][20] Based on its success in the treatment of symptomatic haze, MMC has been evaluated as a prophylactic agent for the prevention of haze following high-risk PRK. 21,22 We hypothesized that surface ablation over a LASIK flap with adjunctive MMC would result in excellent refractive outcomes and minimize the risk for postoperative corneal haze. We report 10 eyes of 10 patients with flap complications who had phototherapeutic keratectomy (PTK)/PRK followed by prophylactic use of MMC (PTK/PRK/MMC) with the intended refractive outcome of emmetropia.…”
Mitomycin-C can be a useful adjunctive therapy for the prevention of haze when applying surface excimer laser therapy to a cornea following LASIK flap complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.